#AUTL
Autolus Therapeutics ($AUTL) – 13D holder update

• Holder: Blackstone
• Stake: now 7.6% (about $27M)
• Filed: Nov 10 · Schedule 13D/A

📊 Track ownership filings at www.elixstocks.com

Educational purposes only. Not investment advice.

#ActivistInvesting #Stocks #Investing #ElixStocks
Blackstone Inc.: 7.6% of Autolus Therapeutics ($AUTL)
Schedule 13D/A filed Nov 10. Who filed, the stake, and how it changed.
elixstocks.com
November 11, 2026 at 9:16 PM
🚨 $AUTL
In connection with its conference call on November 10, 2026 to discuss its results for the quarter ended September 30, 2026, the Company will utilize an updated corporate presentation, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein ...
SEC Filing: AUTL
Click to view the official SEC document.
www.sec.gov
November 10, 2026 at 12:30 PM
#AUTL Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergenc…

https://www.stocktitan.net/news/AUTL/autolus-therapeutics-presents-longer-term-follow-up-data-from-i1gh1ddbn98o.html?utm_source=stocktitan-bluesky&utm_medium=social
Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Autolus Therapeutics (Nasdaq: AUTL) presented longer-term Phase I CARLYSLE results for obe-cel in patients with severe, treatment-resistant systemic lupus erythematosus.At the August 11, 2026 cutoff, 15 patients had received obe-cel, with adult follow-up extending to 25.5 months. Disease activity scores improved, and DORIS remission criteria were achieved by most participants, including 100% followed for at least six months. Among participants followed for at least six months, complete renal response occurred in 6/9 (66.7%) at any time after infusion; one participant (11.1%) achieved partial renal response, beginning at Month 7. No severe renal flares were observed.No ICANS neurological toxicity, HLH/IEC-HS inflammatory syndromes or Grade ≥3 cytokine release syndrome occurred. Obe-cel is also being evaluated in the Phase II LUMINA trial for severe, treatment-resistant lupus with active lupus nephritis, using a single 50M dose.
www.stocktitan.net
November 10, 2026 at 9:05 PM
#$AUTL weekly close $1.52 (-1.3% w/w), below SMA50 $1.91 / below SMA200 $1.67, RSI 36.6. Support $1.48, resistance $1.87. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/autolus-ther...
October 30, 2026 at 9:33 PM
#$AUTL weekly close $1.52 (-1.3% w/w), below SMA50 $1.91 / below SMA200 $1.67, RSI 36.6. Support $1.48, resistance $1.87. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/autolus-ther...
October 30, 2026 at 9:33 PM
$IVV-2 $MIR-2 $IREN-2 $EQT-2 $CHTR-2 $WULF-2 $CSCO-2 $EPD-2 $ICHR-2 $WMG-2 $AR-2 $CMG-2 $BULL-1 $META-1 $ARHS-1 $GFL-1 $MBLY-1 $VCRM-1 $APP-1 $NVDL-1 $SNDK-1 #$SKYD.WS-1 $CVS-1 $AUTL-1 $XLV-1 $CHWY-1 $ANDE-1 $EL-1 $ARKG-1
October 29, 2026 at 8:46 PM
$AUTL — Q3 results on 10 Nov.

Information only — not investment advice.

https://www.merlintrader.com/autolus-therapeutics-stock-hub/
October 27, 2026 at 8:29 PM
#$AUTL closed at $1.54, below the 50-day EMA ($1.83) and the 200-day ($1.72), just above the 20-day low ($1.50). Tested support sits at $1.36-$1.40. RSI 34.

Interactive chart at JC Just Charts: justcharts.merlintrader.com#AUTL
Not investment advice.
JustCharts: Stock Charts & Technical Analysis | Merlintrader
Explore US stock charts with EMA 50 and 200, support, resistance, trendlines and conditional technical scenarios. Daily data from the Merlintrader hub universe.
justcharts.merlintrader.com
October 25, 2026 at 3:16 PM
#$AUTL daily chart
Friday -7.0% to $1.60 on 2.35M shares.
Lupus follow-up at ACR; ALARIC data by year-end.
Support $1.17 / resistance $1.68.
Hub: www.merlintrader.com/autolus-ther...
October 18, 2026 at 7:53 PM
AUTL Q2 2026 earnings: Revenue $46M (+118.4%) · EPS $-0.15. Autolus doubled AUCATZYL sales to $45.7M (+118%) and turned gross margin positive at ~55%, narrowing its net loss to $39.1M; a raised $140–150M 2026 guide and a $75M Perceptive lo…
https://financialreportinsights.com/companies/autl/2026/q2
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings: Revenue $46M (+118.4%)
Autolus doubled AUCATZYL sales to $45.7M (+118%) and turned gross margin positive at ~55%, narrowing its net loss to $39.1M; a raised $140–150M 2026 guide and a $75M Perceptive loan stretch cash into Q2 2028.
financialreportinsights.com
October 8, 2026 at 11:10 PM
October 5: longer CARLYSLE follow-up of obe-cel in severe, refractory lupus comes as an ACR Convergence poster on November 10.
Autolus (#$AUTL): Can AUCATZYL Sustain Its Commercial Momentum?
www.merlintrader.com/autolus-ther...
Autolus ($AUTL): AUCATZYL And The Next Clinical Tests
Autolus ($AUTL): AUCATZYL sales, margins, cash, financing warrants and the next lupus and amyloidosis data, with dated primary sources.
www.merlintrader.com
October 6, 2026 at 8:32 AM
Autolus (#$AUTL): RMAT Designation for Obe-cel in Lupus, ACR Data in November

Free Biotech Catalyst Calendar on Merlintrader.

www.merlintrader.com/autolus-ther...
September 23, 2026 at 9:43 PM
I fear to watch, and yet I cannot turn away.

www.youtube.com/watch?v=Autl...
Therein Lies The Game (The Simpsons)
YouTube video by ThingsICantFindOtherwise
www.youtube.com
August 12, 2024 at 4:05 PM
Dropping TONIGHT, March 3rd in the CappySpace Bazaar: meet Gorinar Scute and Standard Autl! Drop is at 9pm EST at www.cappyspace.com/bazaar.html

#glyos #glyosdrop #cappyspace #mischeivers #indietoys
March 3, 2025 at 6:34 PM
$CONY-1 $GTM-1 $IMVT-1 $GPIQ-1 $ASX-1 $CVE-1 $BOIL-1 $USB-1 $PATH-1 $NTLA-1 $FPS-1 $ETHE-1 $FTAI-1 $CHTR-1 $BEKE-1 $EMXC-1 $SRAD-1 $IEUR-1 $OMER-1 $GDC-1 $CG-1 $FCX-1 $SHOP-1 $KGC-1 $MXL-1 $TMF-1 $TEM-1 $AUTL-1 $ACDC-1 $MUR-1 $DXCM-1 $OVID-1 $BP-1 $CRWV-1 $STTK-1
August 19, 2026 at 8:29 PM
$IBIT-2 $EYE-2 $ACHR-2 $FBTC-2 $SPCF-2 $ARKK-2 $SOXL-2 $ENPH-2 $KGC-2 $CTSH-2 $MU-2 $MRVL-2 $HONA-2 $UPRO-2 $KVYO-2 $IVV-2 $FAST-2 $MP-1 $GOOG-1 $KO-1 $VG-1 $KEN-1 $TNA-1 $QLD-1 $USAR-1 $JBL-1 $NN-1 $CGGR-1 $MSFU-1 $AUTL-1 $SILJ-1 $CRWD-1 $TE-1 $BKNG-1
August 11, 2026 at 8:22 PM
Needham重申买入评级,Autolus Therapeutics(AUTL)目标价维持10美元展望乐观

https://qian.cx/posts/A0D5DBCC-7C00-47EF-B8A6-35DAB1BD3B07
September 23, 2025 at 7:10 AM